The Rheos Baroreflex Hypertension Therapy System offers a novel device-based approach to treating resistant hypertension by electrically activating the carotid baroreflex.
Resistant hypertension has a high prevalence and is associated with high morbidity and mortality. The Rheos Baroreflex Hypertension Therapy System is an implantable device that offers a completely new approach to treating patients with resistant hypertension by electrically activating the carotid baroreflex. Preliminary results from current feasibility clinical trials have shown sustained decreases in blood pressure after 1 year. The pivotal trial for US FDA approval and market release is currently ongoing. This article profiles the Rheos System and evaluates the treatment of resistant hypertension in general.
Scheffers et al. (2007) studied this question.